Home    About Us    Medic-All    Bio B2B    Hot Topic     Expo     Login | Join Now          
Bio B2B 〉ScinoPharm Taiwan, Ltd.

ScinoPharm Taiwan, Ltd.

Chat Now My Favorites
Founded in 1997, with initial on-site operations beginning in November 1999, ScinoPharm offers a wide array of process R&D services and API manufacturing capabilities designed to satisfy customers' exact requirements and facilitate their rapid market introductions. ScinoPharm specializes in process R&D and the production of CGMP Active Pharmaceutical Ingredients (APIs).

ScinoPharm targets three market segments in the global pharmaceutical industry:
  • Custom Synthesis for early phase pharmaceutical activities , including the supply of gram quantities for use as building blocks, drug screening, purity standards, etc. ScinoPharm can supply CGMP materials beginning at the IND stage and continuing through clinical needs as well as launch and post-launch supply requirements.
  • Generic API manufacturing with products provided years before originator/brand patents expire. Processes are guaranteed to be non-infringing, and products are supplied at price-competitive levels. Exclusive or semi-exclusive supply arrangements can be provided.
  • Brand company outsourcing services are available utilizing ScinoPharm's complete scale of CGMP-qualified equipment, built and operated to Western API standards.
Injectable plant facility for high potency cytotoxics will be available. ScinoPharm expanded into the field of oncological injectable formulation, providing one-stop-shop service for our existing API customers. The company also adopts Double A (API+ANDA) business model to team up with Pharma co.'s to apply for ANDA in US/EU and export final drug products globally. ScinoPharm will vertically integrate to develop dossiers for difficult-to-make APIs and to increase our value proposition in the supply chain.
  • Cheng Kao-Huei / Chairman

    Cheng Kao-Huei / Chairman

    Mr. Cheng is also the Honorary Chairman of Tainan Spinning Co.,Ltd. and the director of Uni-President Enterprises Corp.
  • Yung-Fa Chen / CEO

    Yung-Fa Chen / CEO

    Dr.Chen has abundant experience in chemical & pharmaceutical R&D, supply chain management, quality control and assurance, cGMP compliance and formulation development.
  • Portia Lin / VP of Marketing and Sales

    Portia Lin / VP of Marketing and Sales

    Dr.Lin is in charge of the Marketing
    & Sales team for global sales activities for generic products and for Contract Research and Manufacturing business.
  • Chih-Fang(Freon)Chen / VP of Operations

    Chih-Fang(Freon)Chen / VP of Operations

    Mr.Chen has more ore than 25 years experience in chemical production management and enhancing productivity and production efficiency by introducing improvement initiatives and refining systems.
  • Kevin Yen | VP of Administration

    Kevin Yen | VP of Administration

    Mr.Yen has held a number of managerial positions in the areas of finance, accounting, and treasury within Uni-President Enterprise Corp and its affiliates.
  • Gloria Chang | VP of INJ Business

    Gloria Chang | VP of INJ Business

    Dr. Chang has progressed through a series of increasingly responsible positions. She had leaded ARD, biotech, peptide product and pharmaceutical development and quality management division.
Founded in 1997, with initial on-site operations beginning in November 1999, ScinoPharm offers a wide array of process R&D services and API manufacturing capabilities designed to satisfy customers' exact requirements and facilitate their rapid market introductions. ScinoPharm specializes in process R&D and the production of CGMP Active Pharmaceutical Ingredients (APIs).

ScinoPharm targets three market segments in the global pharmaceutical industry:
  • Custom Synthesis for early phase pharmaceutical activities , including the supply of gram quantities for use as building blocks, drug screening, purity standards, etc. ScinoPharm can supply CGMP materials beginning at the IND stage and continuing through clinical needs as well as launch and post-launch supply requirements.
  • Generic API manufacturing with products provided years before originator/brand patents expire. Processes are guaranteed to be non-infringing, and products are supplied at price-competitive levels. Exclusive or semi-exclusive supply arrangements can be provided.
  • Brand company outsourcing services are available utilizing ScinoPharm's complete scale of CGMP-qualified equipment, built and operated to Western API standards.
Injectable plant facility for high potency cytotoxics will be available. ScinoPharm expanded into the field of oncological injectable formulation, providing one-stop-shop service for our existing API customers. The company also adopts Double A (API+ANDA) business model to team up with Pharma co.'s to apply for ANDA in US/EU and export final drug products globally. ScinoPharm will vertically integrate to develop dossiers for difficult-to-make APIs and to increase our value proposition in the supply chain.
Pipeline & Platform
On-Market Product
Contract Service